Application of compound probiotics in preparation of probiotic agent for improving growth performance and immunity of pigs

Through the combination of Bacillus coagulis and Lactate Picocci in complex probiotic agents, the growth performance and immunity of pigs have been significantly improved, and the shortcomings of the existing technology in improving pig growth performance and immunity are solved, and safe and efficient microorganisms are achieved. Intervention effect.

CN118931795APending Publication Date: 2024-11-12漯河微康农业生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411290928.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has shortcomings in improving pig growth performance and immunity, especially in the case of increasing feed costs and increasing negative impacts from antibiotic use, and there is a lack of effective microbial intervention strategies.

Method used

The complex probiotic consists of the Bacillus coagulans BC66 strain with the storage number CGMCC 21879 and the Pediococcus acidilacticici PA153 strain with the storage number CGMCC 2023230, and the specific live bacterial number and dosage form design. Significantly improve pig growth performance and immunity, providing a brand new microbial intervention strategy.

Benefits of technology

It significantly improves the growth performance and immunity of pigs, enhances the balance of intestinal flora, improves the digestion and absorption of nutrients, and reduces the excretion of nutrients in the feed. Moreover, due to the high safety of the two strains, it is difficult to develop resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931795A_ABST
    Figure CN118931795A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a compound probiotic in preparation of a probiotic agent for improving the growth performance and immunity of pigs. The compound probiotic is prepared from a bacillus coagulans BC66 strain and a pediococcus acidilactici PA153 strain, wherein the bacillus coagulans BC66 strain and the pediococcus acidilactici PA153 strain are used for improving the growth performance and immunity of the pigs. The invention creatively finds that the growth performance and immunity of pigs can be remarkably improved by compounding the BC66 strain and the PA153 strain for use, the two strains have a potential mutual matching relationship, the effects are synergistic, and compared with a single BC66 strain or PA153 strain, the growth performance and immunity of the pigs can be remarkably improved under the condition that the total use bacterium amount is consistent, and compared with the single BC66 strain or PA153 strain, the growth performance and immunity of the pigs can be remarkably improved. The effect of the compounding mode of the two bacteria is obviously improved. Therefore, the probiotic agent provides a brand new strategy for improving the growth performance and immunity of pigs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms and relates to the application of a composite probiotic in the preparation of a probiotic agent capable of improving the growth performance and immunity of pigs. Background Art

[0002] With the continuous development of intensive farming in my country, feed costs are constantly increasing. Improving feed utilization and reducing the pollution caused by the excretion of nutrients in feed have become a hot topic for researchers. With the changes in social and economic conditions and the improvement of people's living standards, people are increasingly concerned about the negative impact of using antibiotics and chemicals as additives in feed.

[0003] Probiotics, also known as probiotics and probiotics, are made from beneficial microorganisms selected from nature through special processing. They have multiple functions such as regulating the balance of intestinal microecology, enhancing animal immunity, and promoting growth and development. In today's modern agricultural context of pursuing efficiency, safety, and sustainability, probiotics, as a representative of a new generation of biotechnology, have shown unprecedented potential in the field of pig farming and are leading a profound change in the farming industry.

[0004] Microecological preparations have the advantages of being green, safe, and efficient. Probiotics can regulate gastrointestinal flora, promote the metabolism and absorption of nutrients in the animal body, maintain the dynamic balance of the internal environment, and regulate immunity and allergic reactions. Studies have shown that probiotics can competitively inhibit the growth of harmful bacteria, regulate the balance of intestinal microecology, and probiotics and their metabolites can promote the production of digestive enzymes in the body, accelerate the absorption of nutrients, and improve the production function of animals. Therefore, probiotics have been widely used in animal husbandry production. Therefore, it is very meaningful to develop more microbial intervention strategies to improve pig growth performance and immunity. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide an application of a composite probiotic in the preparation of a probiotic agent for improving the growth performance and immunity of pigs.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides an application of a composite probiotic in the preparation of a probiotic for improving the growth performance and immunity of pigs, wherein the composite probiotic consists of a Bacilluscoagulans BC66 strain with a preservation number of CGMCC 21879 and a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

[0008] The present invention creatively finds that the compound use of BC66 strain and PA153 strain can significantly improve the growth performance and immunity of pigs, and there is a potential mutual cooperation relationship between the two strains, which synergizes the above-mentioned effects. When the total bacterial amount is the same, the effect of the compounding method of the two bacteria is significantly improved compared with the single BC66 strain or PA153 strain. Therefore, the probiotic agent provides a new strategy for improving the growth performance and immunity of pigs. Since Bacillus coagulans and Pediococcus acidilactici are both probiotics, they are highly safe and not easy to produce resistance when used to prepare related efficacy products.

[0009] Preferably, the ratio of the number of viable cells of the BC66 strain to that of the PA153 strain is (1-5):1, for example 1:1, 3:2, 2:1, 5:2, 3:1, 7:2, 4:1, 9:2, 5:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0010] Based on the potential interaction between the BC66 strain and the PA153 strain, the present invention also found that when the two strains are used in combination at the above-mentioned specific ratio of viable bacteria count, their effects in improving the growth performance and immunity of pigs are more significant.

[0011] Preferably, the total number of viable bacteria in the probiotic is not less than 1×10 11 CFU / g or 1×10 11 CFU / mL, for example 1×10 11 CFU / mL (CFU / g), 5×10 11 CFU / mL (CFU / g), 1×10 12 CFU / mL (CFU / g), 5×10 12 CFU / mL (CFU / g), 1×10 13 CFU / mL (CFU / g), 1×10 14 CFU / mL (CFU / g), etc.; other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0012] Preferably, the dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule. The dosage form of the probiotics involved in the present invention is not limited, including the most commonly used lyophilized powder, or further prepared capsule, tablet or granule.

[0013] Preferably, the probiotic is in the form of a freeze-dried powder, and the probiotic is prepared by a method comprising the following steps:

[0014] The BC66 strain and the PA153 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain BC66 bacterial powder and PA153 bacterial powder; the BC66 bacterial powder and the PA153 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.

[0015] Preferably, the protective agent comprises any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

[0016] In a second aspect, the present invention provides a pig feed for improving the growth performance and immunity of pigs, wherein the pig feed comprises a basic feed and a probiotic, wherein the strains in the probiotic are composed of a Bacillus coagulans BC66 strain with a preservation number of CGMCC 21879 and a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

[0017] Preferably, the total viable bacteria count in the pig feed is not less than 1×10 7 CFU / g or 1×10 7 CFU / mL, for example 1×10 7 CFU / mL (CFU / g), 1×10 8 CFU / mL (CFU / g), 5×10 8 CFU / mL (CFU / g), 1×10 9 CFU / mL (CFU / g), 5×10 9 CFU / mL (CFU / g), 1×10 10 CFU / mL (CFU / g), 1×10 11 CFU / mL (CFU / g), 1×10 12 CFU / mL (CFU / g), etc.; other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0018] Preferably, the ratio of the number of viable cells of the BC66 strain to that of the PA153 strain is (1-5):1, for example 1:1, 3:2, 2:1, 5:2, 3:1, 7:2, 4:1, 9:2, 5:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0019] Preferably, the dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule. The dosage form of the probiotics involved in the present invention is not limited, including the most commonly used lyophilized powder, or further prepared capsule, tablet or granule.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The present invention creatively finds that the compound use of BC66 strain and PA153 strain can significantly improve the growth performance and immunity of pigs, and there is a potential mutual cooperation relationship between the two strains, which synergizes the above-mentioned effects. When the total bacterial amount is the same, the effect of the compounding method of the two bacteria is significantly improved compared with the single BC66 strain or PA153 strain. Therefore, the probiotic agent provides a new strategy for improving the growth performance and immunity of pigs. Since Bacillus coagulans and Pediococcus acidilactici are both probiotics, they are highly safe and not easy to produce resistance when used to prepare related efficacy products.

[0022] The BC66 strain involved in the present invention is classified and named Bacillus coagulans. The preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration. The preservation time is March 8, 2021. The preservation number is CGMCC 21879. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0023] The PA153 strain involved in the present invention is classified and named Pediococcus acidilactici PA153, the preservation unit is China Center for Type Culture Collection, the preservation time is March 2, 2023, the preservation number is CCTCC NO: M 2023230, and the address is: Wuhan University, Wuhan, China. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a statistical chart showing the effects of different treatments on the number of lactic acid bacteria in the jejunum of piglets;

[0025] Figure 2 This is a statistical chart showing the effects of different treatments on the number of E. coli in the jejunum of piglets;

[0026] Figure 3 This is a statistical chart showing the effects of different treatments on the number of lactic acid bacteria in the cecum of piglets;

[0027] Figure 4 This is a statistical chart showing the effects of different treatments on the number of E. coli in the piglet cecum;

[0028] Figure 5This is a statistical chart showing the effects of different treatments on the height of the jejunal villi of piglets;

[0029] Figure 6 This is a statistical chart showing the effects of different treatments on the height of the cecal villi in piglets. DETAILED DESCRIPTION

[0030] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0031] The culture medium formula involved in the following examples is as follows:

[0032] MRS medium (g / L): peptone 10 g / L, beef extract 10 g / L, glucose 20 g / L, sodium acetate 2 g / L, yeast powder 5 g / L, diammonium hydrogen citrate 2 g / L, K2PO4·3H2O 2.6 g / L, MgSO4·7H2O 0.1 g / L, MnSO4 0.05 g / L, Tween 80 1 mL / L, cysteine ​​hydrochloride 0.5 g / L.

[0033] Preparation Example 1

[0034] This preparation example provides two kinds of bacterial powder products:

[0035] (1) The BC66 strain was inoculated into an MRS liquid culture medium and cultured at 37°C for 18 h for activation, and the activation was repeated twice to obtain an activated solution; the activated solution was inoculated into an MRS liquid culture medium at an inoculum amount of 2% (v / v), and cultured at 37°C for 24 h to obtain a bacterial solution; the bacterial solution was centrifuged at 3000 rpm for 10 min at 4°C, filtered, and the bacterial bodies were obtained, which were mixed with a protective agent (20% skim milk) of twice the mass, and spray-dried to obtain BC66 bacterial powder with a viable bacterial count of 1×10 11 CFU / g, for future use.

[0036] (2) The PA153 strain was inoculated into MRS liquid culture medium and cultured at 37°C for 24 h for activation. The activation was repeated twice to obtain an activated solution. The activated solution was inoculated into MRS liquid culture medium at an inoculum rate of 4% (v / v) and cultured at 37°C for 24 h to obtain a bacterial solution. The bacterial solution was centrifuged at 3000 rpm for 10 min at 4°C and filtered to obtain bacterial bodies, which were mixed with a protective agent (20% skim milk) of twice the mass and freeze-dried to obtain PA153 bacterial powder with a viable cell count of 1×10 11 CFU / g, for future use.

[0037] Preparation Example 2

[0038] This preparation example provides the following composite probiotic product:

[0039] (1) Double-bacteria compound probiotic agent 1: Evenly mix BC66 powder and PA153 powder in a mass ratio of 1:1 to obtain the product.

[0040] (2) Dual-bacteria compound probiotic agent 2: Mix BC66 powder and PA153 powder in a mass ratio of 5:1 to obtain the product.

[0041] (3) Dual-bacteria compound probiotic agent 3: Evenly mix commercially available Bacillus coagulans ATCC7050 powder and commercially available Pediococcus acidilactici ATCC8042 powder at a live bacteria count ratio of 1:1 to obtain the dual-bacteria compound probiotic agent 3.

[0042] Example

[0043] Effects of probiotics on growth performance and immunity of piglets:

[0044] (1) Experimental animals and groups:

[0045] A total of 240 healthy piglets with similar body weight at 25 days of age were selected, with an average body weight of (7.18±0.38) kg. The 240 piglets were equally divided into 6 groups, with 2 replicates in each group and 20 pigs in each replicate, namely: control group, BC66 intervention group (denoted as S1), PA153 intervention group (denoted as S2), BC66 combined with PA153 intervention group 1 (denoted as S3), BC66 combined with PA153 intervention group 2 (denoted as S4), and ATCC7050 combined with ATCC8042 intervention group (denoted as S5).

[0046] (2) Intervention methods:

[0047] The control group was fed with a basal diet, and each probiotic intervention group was fed with a basal diet supplemented with different probiotics (the total amount of probiotics added in each group was 1.0×10 7 CFU / g), the experiment lasted for 35 days, during which the piglets ate freely. The composition of the basic diet is shown in the table below.

[0048]

[0049]

[0050] (3)Indicator analysis:

[0051] (3.1) The weight of each group of experimental piglets was weighed and recorded before and after the experiment. The feed intake and diarrhea of ​​each group of piglets were recorded daily during the experiment. The average daily weight gain, average daily feed intake, feed-to-meat ratio and diarrhea rate were calculated. The statistical results are shown in Table 1.

[0052] Table 1

[0053]

[0054]

[0055] From the data results in Table 1, it can be seen that compared with the control group, the probiotic agent involved in the present invention can significantly increase the daily weight gain of piglets, reduce the feed-to-meat ratio and diarrhea rate. By comparing the results of S1, S2, S3, and S4, it can be seen that the BC66 strain and the PA153 strain have a synergistic effect on the above effects (* indicates significant difference compared with the control group, p < 0.05).

[0056] (3.2) After 30 days of feeding, the feces of each group of piglets were collected and dried, crushed and sieved, and then crude fat, crude protein, crude fiber, calcium and total phosphorus were measured respectively, and the digestibility was calculated. The detection method was based on the determination of the content of each nutrient in fecal samples in NY / T816-2004. The statistical results are shown in Table 2.

[0057] Table 2

[0058]

[0059] From the data results in Table 2, it can be seen that, compared with the control group, the probiotics involved in the present invention can significantly improve the digestion and absorption utilization rate of nutrients in piglets, improve gastrointestinal digestive function, and improve the digestion and metabolism of nutrients in the diet. By comparing the results of S1, S2, S3, and S4, it can be seen that the BC66 strain and the PA153 strain have a synergistic effect on the above effects (* indicates significant difference compared with the control group, p < 0.05).

[0060] (3.3) After the experiment, 10 mL of jugular blood was collected from 4 pigs in each group, centrifuged at 3500 r / min for 10 min, and the upper serum was frozen at -20°C for testing serum immune indicators including IgA, IgG, IgM and IL-2. The statistical results are shown in Table 3.

[0061] Table 3

[0062] Group IgA (g / L) IgG(g / L) IgM (g / L) IL-2 (ng / mL) Control group 0.365±0.019 1.61±0.11 0.19±0.02 110.53±0.40 S1 0.416±0.021* 2.03±0.14* 0.24±0.01* 111.40±0.49 S2 0.389±0.018 1.78±0.12 0.21±0.01 110.87±0.41 S3 0.435±0.020* 2.18±0.14* 0.26±0.01* 111.67±0.45 S4 0.440±0.018* 2.21±0.13* 0.28±0.02* 111.93±0.48 S5 0.381±0.015 1.75±0.12 0.20±0.01 110.75±0.43

[0063] From the data results in Table 3, it can be seen that the probiotics involved in the present invention can significantly increase the immunoglobulin level in the blood of piglets compared with the control group. By comparing the results of S1, S2, S3, and S4, it can be seen that the BC66 strain and the PA153 strain have a synergistic effect on the above effects (* indicates significant difference compared with the control group, p < 0.05).

[0064] (3.4) After the experiment, each group selected 4 pigs of similar weight for slaughter. After slaughter, the thymus, liver, spleen, and tonsils were removed and weighed after removing the attached fat to calculate the immune organ index. Immune organ index = immune organ weight / live weight. The statistical results are shown in Table 4.

[0065] Table 4

[0066] Group Thymus index Liver index Spleen index Tonsillar index Control group 1.42±0.12 29.15±1.03 2.78±0.31 1.36±0.25 S1 1.47±0.16 32.67±1.14* 3.96±0.62* 1.42±0.19 S2 1.45±0.17 30.15±1.08 3.54±0.43 1.39±0.15 S3 1.50±0.09* 34.13±1.11* 4.13±0.52* 1.45±0.18 S4 1.52±0.13* 34.66±1.14* 4.18±0.44* 1.47±0.16 S5 1.46±0.19 29.95±1.12 3.04±0.38 1.38±0.20

[0067] From the data results in Table 4, it can be seen that compared with the control group, the probiotics involved in the present invention can significantly improve the immune organ index of piglets, indicating that the immune function of weaned piglets is effectively improved. By comparing the results of S1, S2, S3, and S4, it can be seen that the BC66 strain and the PA153 strain have a synergistic effect on the above effects (* indicates significant difference compared with the control group, p < 0.05).

[0068] (3.5) The jejunal and cecal digesta of the slaughtered piglets of each group were collected and frozen at -80℃ for the detection of intestinal flora. The number of Escherichia coli and Lactobacillus in the jejunum and cecum was determined by plate counting method. The results are as follows: Figure 1-Figure 4 shown.

[0069] As can be seen from the figure, compared with the control group, the probiotics involved in the present invention can significantly increase the number of lactobacilli in the intestines of piglets and reduce the number of Escherichia coli, indicating that it can improve the disorder of intestinal flora in piglets and maintain the balance of intestinal flora. By comparing the results of S1, S2, S3, and S4, it can be seen that the BC66 strain and the PA153 strain have a synergistic effect on the above effects.

[0070] (3.6) About 1 cm of the jejunum and ileum were collected from the slaughtered piglets of each group, cleaned with 0.9% NaCl, fixed in 4% formaldehyde, stained with hematoxylin-eosin, observed under a microscope, photographed with the Motic Digital Slice Management System, and measured with the MoticImagesPlus 2.0 microscope imaging software for the height of the villi in the jejunum and ileum. The results are shown in Figure 5-Figure 6 shown.

[0071] As can be seen from the figure, compared with the control group, the probiotic agent involved in the present invention can significantly increase the height of the villi in the intestine of piglets, indicating that it can promote the development of the intestine of piglets, promote the maturation of small intestinal cells, ensure the integrity of intestinal function, and thus improve the utilization rate of feed. By comparing the results of S1, S2, S3, and S4, it can be seen that the BC66 strain and the PA153 strain have a synergistic effect on the above effects.

[0072] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0073] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0074] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. Application of a composite probiotic in the preparation of a probiotic for improving pig growth performance and immunity, It is characterized in that The composite probiotics consist of Bacillus coagulans BC66 strain with a preservation number of CGMCC 21879 and Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230.

2. The use according to claim 1, It is characterized in that The ratio of the number of viable bacteria of the BC66 strain to that of the PA153 strain is (1-5):

1.

3. The use according to claim 1, It is characterized in that The total number of viable bacteria in the probiotic is not less than 1×10 11 CFU / g or 1×10 11 CFU / mL.

4. The use according to claim 1, It is characterized in that The dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule.

5. The use according to claim 4, It is characterized in that The dosage form of the probiotic is a freeze-dried powder, and the probiotic is prepared by a method comprising the following steps: The BC66 strain and the PA153 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain BC66 bacterial powder and PA153 bacterial powder; the BC66 bacterial powder and the PA153 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.

6. The use according to claim 5, It is characterized in that The protective agent includes any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

7. A pig feed for improving pig growth performance and immunity, It is characterized in that The pig feed comprises a basic feed and a probiotic agent, wherein the strains in the probiotic agent are composed of a Bacilluscoagulans BC66 strain with a preservation number of CGMCC 21879 and a Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M2023230.

8. The pig feed according to claim 7, It is characterized in that The total number of viable bacteria in the pig feed is not less than 1×10 7 CFU / g or 1×10 7 CFU / mL.

9. The pig feed according to claim 7, It is characterized in that The ratio of the number of viable bacteria of the BC66 strain to that of the PA153 strain is (1-5):

1.

10. The pig feed according to claim 7, It is characterized in that The dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule.